Natera, Inc. $NTRA Stock: Robeco Institutional Asset Management B.V. Decreases Position

Robeco Institutional Asset Management B.V. cut its position in shares of Natera, Inc. (NASDAQ:NTRA) by 45.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 223,309 shares of the medical research company’s stock after selling 185,307 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.15% of Natera worth $92,296,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc raised its holdings in shares of Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after acquiring an additional 36 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 47 shares during the last quarter. Raiffeisen Bank International AG boosted its position in shares of Natera by 48.5% during the 2nd quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 49 shares during the last quarter. First Horizon Corp grew its holdings in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares in the last quarter. Finally, Purus Wealth Management LLC grew its holdings in shares of Natera by 5.3% in the third quarter. Purus Wealth Management LLC now owns 1,135 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 57 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NASDAQ NTRA opened at $413.38 on Thursday. The business’s 50 day moving average price is $363.64 and its 200-day moving average price is $280.16. Natera, Inc. has a fifty-two week low of $181.00 and a fifty-two week high of $437.41. The company has a market cap of $59.59 billion, a P/E ratio of -303.95 and a beta of 1.50.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. Natera’s revenue was up 37.7% on a year-over-year basis. During the same period last year, the company earned ($0.74) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.05 EPS for the current year.

Insider Activity

In related news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00. Following the completion of the transaction, the insider directly owned 106,914 shares of the company’s stock, valued at approximately $44,285,917.08. The trade was a 2.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brophy sold 478 shares of Natera stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16. Following the transaction, the chief financial officer directly owned 51,637 shares of the company’s stock, valued at approximately $14,159,898.14. This represents a 0.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 52,985 shares of company stock worth $16,119,137. Insiders own 5.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NTRA shares. Stephens boosted their price target on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Royal Bank Of Canada lifted their price objective on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Citigroup boosted their target price on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $374.64.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.